Activated Prothrombin Complex Concentrate

PreclinicalSmall molecule

Activated Prothrombin Complex Concentrate is one of 26 small molecule programs targeting Von Willebrand disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Hemophilia aActive, not recruiting

Von Willebrand DiseasePreclinical

Active, not recruiting

Hemophilia aPreclinical

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Approved

16 2

Rayos

RRoxane Laboratories

Approved

1 3

Cyklokapron

Efanesoctocog Alfa

7 5

Advate

Takeda

Phase 3

4 6

Marstacimab

Pfizer

Phase 3

1 7

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

1 8

Rfviia

Roche

Phase 3

2 9

PF-06741086

Pfizer

Phase 3

2 10

SCT800

SSinocelltech Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Active, not recruiting

Von Willebrand Disease, Type 3

NCT06883240

Q2 2029

Recruiting

Hemophilia a

NCT04023019

Clinical

Trials by Indication[1]

Hemophilia A2 trials

Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting·EEmory University··NCT04023019·120 enrolled

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

Completed·TTulane University School of Medicine·Phase 2/3·NCT00221195·34 enrolled

Von Willebrand Disease, Type 31 trial

A Multicenter Non-Interventional Study Evaluating Bleeds and Health-Related Quality Of Life in Patients With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Active, not recruiting· Roche logo

Roche··NCT06883240·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Activated Prothrombin Complex Concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Activated Prothrombin Complex Concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Activated Prothrombin Complex Concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

Activated Prothrombin Complex Concentrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Trials by Indication[1]

Hemophilia A2 trials

Von Willebrand Disease, Type 31 trial

References

Drug Info

Quick Facts

Related News